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Abstract
Background: Hepatocellular carcinoma (HCC) is rare in patients with autoimmune hepatitis 
(AIH). However, the overall burden of AIH cirrhosis in causing HCC and patients’ risk factors are 
not well understood.
Aims: To characterize the proportion of HCC linked to AIH at a large academic health center, and 
to identify variables associated with HCC in patients with AIH in a case-control study design.
Methods: Over a 14.5-year period, medical records of all patients with HCC were reviewed. 
Cases are AIH patients identified from the cohort and controls are patients with AIH without 
HCC. Three controls were randomly chosen from the Genetic Repository of Autoimmune Liver 
Disease and Coexisting Exposures database for each eligible case.
Results: Out of 1,250 eligible patients, 20 were linked to AIH (1.6%). Their median age was 64 
years, 40% men, and 100% Caucasian. 10% of AIH patients did not have evidence of cirrhosis at 
HCC diagnosis. The proportion of HCCs due to AIH decreased during the time intervals of the 
study. Compared to controls, cases were more likely men (40.0% vs. 18%, P=0.049), with longer 
AIH duration (median 16 years vs. 5 years, P=0.004). Prolonged AIH duration (OR 1.68, p=0.006) 
and older age (OR 1.15, p=0.049) were risk factors for HCC.
Conclusions: AIH is a rare cause (1.6%) for HCC in Midwestern United States with a 
decreasing trend over 14.5 years. 10% of AIH-HCC patients occurs without cirrhosis. Patients 
with prolonged duration of the disease and older age are at high risk to develop HCC.
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Autoimmune hepatitis (AIH) is a rare autoimmune disease affecting predominantly 
Caucasian females. Its prevalence is estimated at 18.3 per 100,000 (95% CI: 17.3–19.4) with 
an incidence peak in middle-aged women.[1] The etiopathogenesis of AIH is likely to be 
explained by complex interactions between environmental exposures and susceptible genetic 
predispositions.[2] Symptoms, severity, and outcomes vary widely according to geographical 
locations and racial distributions. Recent reports suggest a recent increase in the disease 
incidence, prevalence as well as mortality and morbidity rates in both sexes.[3–5]
Hepatocellular carcinoma (HCC) is an important complication in patients with underlying 
liver disease and cirrhosis. It is rare in patients with cirrhosis due to AIH compared to other 
chronic liver disease risk factors; however, these patients are routinely screened for HCC. 
The true incidence of HCC linked to AIH remains unknown due to the lack of large sample 
studies. Large variations exist between reported numbers; it was recently estimated to be 
3.06 per 1000 person-years.[4] In addition, the overall burden of AIH cirrhosis and risk 
factors for developing HCC in AIH in the absence of co-existing etiologies are not well 
understood. Therefore, the cost-effectiveness of established screening strategies in this 
population is controversial. Male gender, prolonged immunosuppressive treatment and 
features of portal hypertension were identified as predictors for HCC in patients with AIH.
[6] In addition to the obvious increased risk of HCC in patients with underlying cirrhosis, 
studies reporting HCC occurring in patients in the absence of cirrhosis are scarce.
Two objectives of this study were: (a) to describe the trend of HCC associated with AIH 
over a 14.5-year period at a large liver center in the Midwestern United States and (b) to 
identify variables associated with HCC in patients with AIH in a case-control study design.
Materials and Methods
All adult patients with HCC seen at Indiana University and Methodist Hospitals in 
Indianapolis, Indiana from January 2000 to June 2014 were retrieved from the Indiana State 
Cancer Registry. Medical records of all such retrieved patients were manually reviewed to 
confirm the diagnosis of HCC. Patients with uncertain HCC diagnosis, fibrolamellar HCC or 
cholangiocarcinoma, insufficient data, or who were seen for tumor recurrence were 
excluded. The demographics, comorbidities, liver disease and tumor characteristics, and 
treatment modalities were obtained from the medical records. The presence of underlying 
cirrhosis was ascertained based on clinical, laboratory, and imaging criteria, as previously 
described by Mittal et al.[7] From this cohort, we identified HCCs associated with AIH 
(AIH-HCC) and compared their proportion relative to all other causes of liver disease over 3 
time intervals (2000–2004; 2004–2009; and 2010 through June 2014).
Subsequently, we conducted a case-control study comprising of AIH-HCC patients (cases) 
and patients with AIH but no HCC (controls) randomly chosen from a database of all AIH 
subjects seen at our facility at least once between the year 2000 and June 2014. An 
autoimmune liver disease database, Genetic Repository of Autoimmune Liver Disease and 
Coexisting Exposures (GRACE), is a well-established repository of all AIH cases evaluated 
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at Indiana University including demographics, clinical data, and biologic samples.[8] At the 
time of the study, the GRACE database contained 350 unique patients. Three random 
controls were selected by SPSS statistical software for each case and were not matched to 
any variable. Medical records for both cases and controls groups were reviewed for AIH-
specific details including AIH duration, medications used, and disease course. 
Demographics, clinical and disease characteristics were compared between the two groups. 
Age at AIH diagnosis was estimated by the difference between the date of birth and the AIH 
diagnosis date. The duration of AIH was calculated by the time difference between the date 
of AIH diagnosis and the date of last contact or death. Serum anti-nuclear antibodies (ANA) 
and anti-smooth muscle antibodies (ASMA) > 1:40 dilutions were considered positive. 
Survival data was obtained from the Cancer Registry and the medical records for AIH 
patients who developed HCC. For patients who are still alive or dead with unknown date of 
death, the date of last contact was utilized to calculate the overall survival.
Statistical Analysis
Continuous variables are presented as mean ± standard deviation (SD) or median with 
interquartile range (IQR), and categorical variables as numbers and percentages. Chi-square 
test was used for comparison between different groups for discrete variables and 
independent-samples, non-parametric tests (Mann-Whitney) for comparison of continuous 
variables. The linear-by-linear progression p-value compared the time-trend between AIH-
HCC and other HCCs. Univariate and multivariate analyses were conducted with HCC as 
the outcome for each variable using logistic regression models. All statistical tests were 
performed using IBM SPSS statistical software version 24. A p-value <0.05 was considered 
as statistically significant.
Results
During the study period, 1,290 unique patients with reported HCC were seen at our 
institution. After excluding 40 patients in whom we could not ascertain the HCC diagnosis 
or had mixed HCC/cholangiocarcinoma, there were 1,250 patients with HCC eligible for 
inclusion in this study. Viral hepatitis with or without alcohol (56%), alcoholic liver disease 
(12.2%), and nonalcoholic fatty liver disease (NAFLD) (16.6%) were other dominant causes 
of underlying liver disease in this cohort. Twenty four patients had underlying AIH: 20 with 
AIH alone whereas 4 with co-existing viral hepatitis or significant alcohol consumption. For 
the remainder of this paper, we focused on 20 patients with HCC developing in patients with 
AIH.
The proportion of HCCs arising in patients with underlying AIH during 2000–2004, 2005–
2009, and 2010 - June 2014 was 3.1%, 1.6%, and 0.9% respectively compared to 96.9%, 
98.4% and 99.1% respectively for HCC cases linked to other etiologies (p=0.02 for the trend 
comparison). Selected characteristics of 20 AIH patients with HCC are described in Table 1. 
Their median age was 64 years with an IQR of 9, their mean body mass index (BMI) was 
30.9 ± SD of 7.4 kg/m2, and all of them were Caucasian. Ninety percent had underlying 
cirrhosis at the time of HCC diagnosis their mean Model for End-Stage Liver Disease 
(MELD) score at presentation was 13.2. Thirty-five percent received a liver transplant, 20% 
Dakhoul et al. Page 3













underwent surgical resection, and 45% had catheter-based therapies. Their 1, 3, and 5-year 
survival rates were 60%, 40%, and 30% respectively. Out of 20 AIH-HCC patients, 9 
patients (45%) were alive at the end date of the study, and 11 (55%) were deceased. Out of 
the 11 deceased patients: 4 (36%) died from liver related complications, 2 (18%) had non-
liver related deaths, and 5 patients (46%) were unknown.
We subsequently compared 20 AIH-HCC patients (Cases) and 60 patients with AIH but no 
HCC (Controls) (Table 2). The median age was 56.6 years (IQR 21.4) vs. 49 years (IQR 21) 
in cases and controls respectively; however, the difference was not significant (p=0.23). 
Cases were more frequently male (40% vs. 18%; p=0.049) and exclusively white (100%). 
The median duration of AIH was significantly longer among AIH-HCC patients (16.3 years) 
compared to controls (5.0 years, p=0.004). A total of 5 patients with AIH-HCC (41.7%) had 
underlying liver cirrhosis at AIH diagnosis compared with 14 (26.9%) of the AIH non-HCC 
group (p=0.31); however, this information was unavailable for 16 patients overall (cases and 
controls). The majority of patients from both groups had positive ANA (68.8% of cases and 
74.5% of controls). On the other hand, only 21.4% of cases had positive ASMA compared to 
70.6% of controls (p=0.001). To compare the course of AIH between the 2 groups, we 
collected the number of clinical relapses throughout disease course. This data was 
unavailable in 65% of the AIH-HCC group and 25% of the control group. In the remaining 
patients, 43% and 53% of the cases and controls respectively had at least one relapse since 
diagnosis (p=0.60).
Medications received by patients were assessed until HCC diagnosis for cases and 
throughout the disease course for controls. Most of the patients from both groups were 
started on steroids (prednisone/budesonide) (62.5% of cases and 78.3% of controls) or 
azathioprine (62.5% of cases and 65% of controls) to treat disease-associated hepatic 
inflammation. Treatment with 6-mercaptopurine or ursodeoxycholic acid (UDCA) was less 
prevalent (20% of cases vs. 15% of controls for 6-mercaptopurine and 15% of cases vs. 12% 
of controls for UDCA). Fourteen percent of cases vs. 1.7% of controls were not on any 
medications (p=0.03). AIH-HCC patients and AIH patients without HCC received liver 
transplantation equally (p=0.19).
As a next step, we performed univariate and multivariate analyses using logistic regression 
models to better understand what variables may be independently associated with HCC in 
AIH patients. We computed this analysis for variables that were different among cases and 
controls with p-values <0.10. These variables include male sex (female sex used as 
reference), AIH duration, positive ASMA and no medications received. Although age was 
not significantly different between the compared groups in our study, we included it in this 
analysis as increased age was reported to be associated with HCC in the literature.[9] This 
multivariate logistic regression analysis showed older age (OR: 1.15, 95% CI 1.001–1.314, 
p=0.049), and increased AIH duration (OR: 1.68, 95% CI: 1.16–2.45, p=0.006) to be 
significant risk factors for developing HCC whereas positive ASMA was again negatively 
associated with HCC (OR: 0.02, 95% CI 0–0.73, p=0.03).
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This study evaluated the disease burden, trend and risk factors of AIH-HCC in a large cohort 
of 1,250 patients with well-characterized HCC from a large tertiary referral center in the 
Midwestern U.S. between 2000 and June 2014. Out of 1,250 patients, we were able to 
identify 20 patients (1.6% of the cohort) with HCC due to underlying AIH. This finding is 
similar to other studies reporting the percentage of HCC associated with AIH to be ≤3%,
[7,10–12] and is significantly lower compared to other etiologies of chronic liver disease.
[4,13] A recently published meta-analysis that included 25 studies estimated an overall HCC 
incidence rate of 3.06 per 1000 patient-years (95% CI, 2.22–4.23) among patients with AIH.
[4] Many studies have suggested an increase in the incidence rate of HCC cases linked to 
AIH.[3–5] Although we cannot draw conclusions regarding the incidence rate of HCC in 
AIH patients from this study, we observed a significant downtrend in the proportion of these 
cases over the 14.5 years of the study compared to the rest of the HCC cases (p=0.02). This 
observation of less HCC over time might be explained by the ability to achieve higher 
frequencies of biochemical response, maintenance of remission, fibrosis stability/regression 
or fewer relapse rates in a majority of AIH patients with current multiple 
immunosuppressive modalities. [14]
HCC usually occurs in patients with cirrhosis, but can also develop in non-cirrhotic livers.
[15] The latter is primarily seen in patients with Hepatitis B[16] and more frequently 
reported recently from NAFLD;[7,17,18] However, HCC occurring in non-cirrhotic patients 
is very rare. HCC patients with AIH arise almost exclusively in cirrhotic livers,[12,13,19,20] 
with a risk of 1.9% per year.[21] Tansel and colleagues reported a pooled HCC incidence 
rate among patients without cirrhosis of 1.14 per 1000 person-years with 95% CI: 0.60–2.17.
[4] Furthermore, they also found that 23% of AIH patients with HCC who did not have liver 
cirrhosis at the time of initial AIH diagnosis eventually developed cirrhosis during follow-
up.[4] In our cohort, 2 patients (10% of AIH-HCC) had no evidence of cirrhosis, both 
biopsy-proven and interestingly males. Although the nature of our center as a tertiary 
referral center might be overestimating the proportion of AIH-HCC cases emerging in the 
absence of cirrhosis, this finding is concerning and should be looked at further at a larger 
scale.
Our data suggest that the duration of the disease and older age are risk factors for liver 
cancer: OR=1.68 for AIH duration (p=0.006) and OR=1.15 for older age (p=0.049). 
Literature assessing the association of the AIH duration and the risk of HCC is scarce. In 
Wang et al study, AIH patients with HCC had a prolonged duration of the illness compared 
to non-HCC patients.[20] Teufal et al also reported a long period of AIH patients who 
developed HCC,[13] but to our knowledge, our study is the first to describe this finding 
regardless of the presence of underlying liver cirrhosis. It remains possible that prolonged 
chronic low-grade hepatocellular inflammation could be a factor associated with HCC 
development. The effect of age on the outcomes of autoimmune hepatitis is controversial. 
Elderly patients present with an acute onset of the disease and have a significantly higher 
frequency of cirrhosis at the time of diagnosis.[22,23] With the known risk of HCC in 
patients with cirrhosis, these results are in agreement with ours. Similarly, Macaron et al [9] 
reported a hazard ratio of 1.1 (p<0.001) for older age which also supports our findings.
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Our study has few limitations. Disease-linked variables such as AIH severity, symptoms at 
presentation, number of relapses, AIH disease course, and causes of deaths were difficult to 
adequately assess because of incomplete electronic medical records. Despite a large number 
of patients with HCC, our cohort still may lack the needed statistical power to show 
differences in outcomes between AIH-HCC and AIH non-HCC subjects because of the low 
frequency of AIH-associated HCC. There is also a small possibility that 3 out of our AIH-
HCC patients may have had concomitant nonalcoholic fatty liver disease viewing the 
presence of 3 risk clinical factors. We still remain enthusiastic about our findings, as our 
resultant sample size of 20 patients (cases) is larger than most similar studies.[6,21,24,25]
In conclusion, AIH is a rare cause (1.6%) for HCC in Midwestern United States. The 
proportion of HCC linked to AIH is downtrending from 3.1% between the year 2000 and 
2004 to 0.9% between 2010 and June 2014 compared to HCC linked to other etiologies. 
10% of HCC patients with AIH occur without underlying liver cirrhosis. AIH Patients with 
prolonged AIH duration and older age are at high risk to develop HCC. Further prospective 
studies are needed to confirm our findings and to explore whether screening for HCC in 
patients with AIH can be limited to a certain subset of subjects with selected risk factors.
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Table 1.
Selected Characteristics of patients with AIH and HCC.
Variables AIH-HCC (n=20)
Baseline Characteristics
Age at HCC diagnosis (years), median (IQR) 64 (9)




Diabetes Mellitus (%) 30
Coronary artery disease (%) 20
Liver Disease Severity
ALT (U/L), mean (SD) 61 (75)
Total bilirubin (mg/dL), mean (SD) 2.9 (2.5)
Albumin (g/dL), mean (SD) 3.0 (0.7)
Platelet count (K/mm3), mean (SD) 110 (83)
MELD, mean (SD) 13.2 (5.5)






Tumor size (cm), median (IQR) 2.6 (2.4)














Orthotopic liver transplantation 35
Catheter delivered therapies 45
Survival Rates (%)



















At any time throughout the disease course
APRI: AST to platelet ratio index; AFP: alpha-fetoprotein; BCLC: Barcelona Clinic Liver Cancer.
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Table 2.
Summary of the comparison analysis results of all variables between AIH patients with and without HCC.
Variables AIH-HCC (n=20) AIH Without HCC (n=60) p-value
Baseline Characteristics
Age at AIH diagnosis (years), median (IQR) 56.6 (21.4) 49.0 (21.0) 0.23






AIH duration (years), median (IQR) 16.3 (17.1) 5.0 (7.3) 0.004
Liver Disease Severity
Liver cirrhosis at AIH diagnosis (%) 41.7 26.9 0.31
Autoimmune Profile
Positive ANA (%) 68.8 74.5 0.65
Positive ASMA (%) 21.4 70.6 0.001
Treatment Modalities Received
*
Medications (%) 62.5 78.3 0.16
Prednisone/Budesonide 62.5 65 0.85
Azathioprine 20 15 0.64
6-Mercaptopurine 15 11.7 0.70
Ursodiol 35 20.3 0.19
None 35 20.3 0.19
Liver Transplantation (%)
*
At any time throughout the disease course
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